DELTA-FLY PHARMA, INC.

DFP-10917 and Venetoclax Combination Trial Advances to Phase II for AML Treatment

3 months ago

• Delta-Fly Pharma's Phase I/II trial evaluating DFP-10917 in combination with Venetoclax has successfully completed the dose-finding phase with positive tolerability results in AML patients. • The Data Management Committee has approved the safety profile in all six patients from Phase I, enabling progression to Phase II efficacy testing. • Multiple potential patients are already lined up to participate in the Phase II portion, indicating strong interest in this second-line therapy option for acute myeloid leukemia.

Delta-Fly Pharma's DFP-10917 Shows Promise in Combination with Venetoclax for AML

7 months ago

• Delta-Fly Pharma's Phase I/II study of DFP-10917 with Venetoclax in AML patients previously treated with Venetoclax is underway, with patient enrollment progressing well. • Early results from the first three patients indicate encouraging safety and efficacy profiles for the DFP-10917 and Venetoclax combination therapy. • The company aims to develop a safer alternative to standard chemotherapy, potentially leading to NDA approval in the US through collaboration with a major pharmaceutical company. • A Phase III study of DFP-10917 in relapsed/refractory AML patients is planned, though data cut-off is affected by a decrease in long-term survivors.